• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • OncoFAP-Radio Conjugates
    • OncoFAP-Drug Conjugate
    • Onco IX (PHC-102, Imaging)
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • OncoFAP-Radio Conjugates
    • OncoFAP-Drug Conjugate
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma

by m.romi | Jul 25, 2022 | 2022, Press Releases, Scientific

More details

Philogen to attend the Peptide Therapeutic Forum 2022 on August 25-26, 2022

by last | Jul 6, 2022 | 2022, Past Events

Philogen announces its attendance at the Peptide Therapeutic Forum 2022. Samuele Cazzamalli, Head of Small Molecule Therapeutics at Philogen, is giving a lecture entitled “Small Molecule Therapeutics as an alternative to Peptide Therapeutics: a clean strategy to...

Philogen to attend the International Mass Spectrometry Congress 2022 in Maastricht (August 27th-September 2nd, 2022)

by last | Jul 6, 2022 | 2022, Past Events

Dr. Ettore Gilardoni, Head of Bio-MS at Philogen, will present a poster entitled: A mass spectrometry-based method for the determination of in vivo biodistribution of small molecule-metal conjugates. Dr. Gilardoni will also give a presentation on August 31st,...

Philogen to the 12th European Post-Chicago Melanoma/Skin Cancer Meeting, 30-1 July

by last | Jun 27, 2022 | 2022, Past Events

Philogen will be Bronze Sponsor of the Post-Chicago Meeting in Münich (30-1 July). Philogen will chair a Satellite Symposium on Friday July 1, 11.30-12.00 am. Dr. Alfredo Covelli, Philogen’s CMO, will give a presentation entitled “Immunocytokines for the therapy...

Philogen to attend the 3rd Annual Cytokine-Based Drug Development Summit, Boston (July 26-29, 2022)

by Lisa Nadal | Jun 27, 2022 | 2022, Past Events, Scientific

Philogen will attend the 3rd Annual Cytokine-Based Drug Development Summit in Boston.   Roberto De Luca, Head of Antibody Therapeutics, will give a virtual lecture entitled “Antibody-cytokine fusion proteins against Fibroblast Activation Protein (FAP)” on the 28...

Philogen to attend the 13th World ADC San Diego 2022, San Diego, USA (6-9 September 2022)

by last | Jun 27, 2022 | 2022, Past Events

Philogen will attend the 13th World ADC in San Diego (USA) in September 2022. Samuele Cazzamalli, Head of Small Molecules Therapeutics at Philogen, will give a lecture in person entitled “Pan-Tumoral Small Molecule-Drug Conjugates Targeting Fibroblasts Activation...
« Older Entries
Next Entries »

Recent Posts

  • Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023
  • Philogen to attend Mid & Small | London 2023 Conference on April 20, 2023
  • Philogen to attend 19th EADO Congress on April 20-22, 2023
  • Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)
  • Philogen to attend the Society for Immunotherapy of Cancer’s 37th Annual Meeting 2022 in Boston (8-12 November 2022)

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch